| 0.0455 -0.008 (-15.58%) | 08-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.07 |
1-year : | 3.32 |
| Resists | First : | 1.77 |
Second : | 2.84 |
| Pivot price | 0.54 |
|||
| Supports | First : | 0.03 |
Second : | 0.03 |
| MAs | MA(5) : | 0.07 |
MA(20) : | 1.03 |
| MA(100) : | 1.74 |
MA(250) : | 97.61 |
|
| MACD | MACD : | -0.6  |
Signal : | -0.6 |
| %K %D | K(14,3) : | 0.3 |
D(3) : | 1 |
| RSI | RSI(14): 22.3 |
|||
| 52-week | High : | 1047 | Low : | 0.03 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SXTC ] has closed above bottom band by 36.4%. Bollinger Bands are 212.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.06 - 0.06 | 0.06 - 0.06 |
| Low: | 0.05 - 0.05 | 0.05 - 0.05 |
| Close: | 0.05 - 0.05 | 0.05 - 0.05 |
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
Fri, 07 Aug 2026
China SXT Pharmaceuticals Inc (SXTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Wed, 05 Aug 2026
China SXT Pharmaceuticals to implement 1-for-80 reverse stock split - Investing.com
Wed, 05 Aug 2026
China SXT will combine every 80 shares into one Aug. 10 - Stock Titan
Wed, 05 Aug 2026
China SXT Pharmaceuticals, Inc. Announces Share Consolidation - Yahoo Finance
Tue, 28 Jul 2026
China SXT Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:SXTC - tradingview.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 38 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 109.4 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 23 (K) |
| Shares Short P.Month | 72 (K) |
| EPS | -9.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 31.01 |
| Profit Margin | 0 % |
| Operating Margin | -153.3 % |
| Return on Assets (ttm) | -15.8 % |
| Return on Equity (ttm) | -27.5 % |
| Qtrly Rev. Growth | -44 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.02 |
| EBITDA (p.s.) | -0.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 1.52 |
| Price to Cash Flow | -0.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|